5 terminated. 5 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 5 |
| Phase 1 | 3 | Terminated 3 |
Follow Advanced Malignant Solid Neoplasm: new trials by email Literature Review of Advanced Malignant Solid Neoplasm trials Research Report on Advanced Malignant Solid Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer Abemaciclib, Biopsy, Bone Scan - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Phase 2 | Terminated | OHSU Knight Cancer Institute | 6 | 2025-06-24 | 2026-04-28 |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Atezolizumab, Avelumab, Durvalumab - Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-14 | 2026-04-30 |
| Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies Anti-CTLA4 Monoclonal Antibody BMS-986218, Nivolumab, Stereotactic Body Radiation Therapy - Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 13 | 2021-03-29 | 2026-03-03 |
| CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study CD24 Extracellular Domain-IgG1 Fc Domain Recombinant Fusion Protein CD24Fc, Placebo Administration - Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | Tianhong Li | 3 | 2020-10-30 | 2026-08-10 |
| Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers Pembrolizumab, Talabostat Mesylate - Advanced Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm | Phase 2 | Terminated | M.D. Anderson Cancer Center | 31 | 2020-03-19 | 2025-05-16 |
Lung Neoplasms (2) · Adrenal Gland Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Liver Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Prostatic Neoplasms (1) · Urinary Bladder Neoplasms (1)
Neoplasms (3) · Neoplasms by Site (3) · Adenocarcinoma (2) · Carcinoma (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Lung Diseases (2) · Male Urogenital Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Respiratory Tract Diseases (2)
Nivolumab (2) · pembrolizumab (2) · Biopsy (1) · Disulfides (1) · Gemcitabine (1) · Immunoglobulin G (1) · Letrozole (1) · NPI 2358 (1) · PT-100 dipeptide (1) · Pemetrexed (1) · Radiation (1) · Radiosurgery (1) · Radiotherapy (1) · Tamoxifen (1) · abemaciclib (1)
M.D. Anderson Cancer Center (3) · OHSU Knight Cancer Institute (1) · Tianhong Li (1)
United States (5)
Aung Naing, MD (1) · Charles D Lopez, MD, PhD (1) · James Welsh (1) · Siqing Fu, MD, PHD (1) · Tianhong Li, MD, PhD (1)
P30CA093373 (1)